EP Patent

EP3654980A1 — Regimens for treating hib infections and aids

Assigned to Janssen Sciences Ireland ULC · Expires 2020-05-27 · 6y expired

What this patent protects

The invention relates to a method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotégravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof of this, in…

USPTO Abstract

The invention relates to a method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotégravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof of this, including the option of interrupting the administration of a first oral anti-retroviral regimen and administering intramuscularly, once four weeks or less often said combination of cabotégravir and rilpivirine.

Drugs covered by this patent

Patent Metadata

Patent number
EP3654980A1
Jurisdiction
EP
Classification
—
Expires
2020-05-27
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Sciences Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.